Toragen Updates: Phase 1 Trial of TGN-S11 for HPV-Linked Stage 4 Cancer

Toragen Inc., a biotechnology firm in San Diego that is currently in the clinical development phase, is concentrating on the creation of highly selective medications aimed at cancers linked to viral infections. The company has reported encouraging safety findings from its active Phase 1 trial of TGN-S11, its small molecule therapeutic candidate, in individuals suffering from HPV-related cancers.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being conducted in two parts: Part 1 is escalating doses of TGN-S11 monotherapy and Part 2 is TGN-S11 in combination with Keytruda®, a PD-1 checkpoint inhibitor. The dose escalation part consists of up to five Cohorts of three to six patients on monotherapy with increasing doses of TGN-S11. The Keytruda® combination part consists of up to five Levels of three to six patients with increasing doses of TGN-S11 and the standard dose of Keytruda®.

In Part 1, 9 patients were treated with TGN-S11 as monotherapy in the first 3 dose cohorts with no safety issues identified. One-third of the patients in this portion of the study showed drug activity with decreases in tumor size and decreases in circulating tumor HPV DNA (ctHPV DNA). In addition, three patients have been treated in Part 2 Level 1 evaluating TGN-S11 in combination with Keytruda® with no safety issues. Two of these 3 patients in this portion of the study showed drug activity with decreases in tumor size and decreases in circulating tumor HPV DNA. One of these 3 patients continues to receive combination therapy and has a 93% reduction in ctHPV DNA. The study is ongoing with patients currently being dosed in Part 1 Cohort 4 and Part 2 Level 2.

“We have been very pleased with the positive safety profile for TGN-S11 in patients who completed the first 3 monotherapy dose cohorts of Part 1 and the first level of Part 2 in combination with Keytruda® in this ongoing Phase 1 trial,” said Dr. Sandra Coufal, Toragen’s CEO. “The drug activity observed in 5 of these 12 subjects is also very encouraging. Based on the current progress, we believe both parts of the study will be completed by the end of 2024.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of November 20, 2024, there are 2 investigational drugs for the HPV E5 target, including 4 indications, 1 R&D institution involved, with related clinical trial reaching 1, and as many as 121 patents.

TGN-S11 is a small molecule drug developed by Toragen, Inc. It targets the HPV E5 protein and is intended for the treatment of neoplasms and infectious diseases. The drug is specifically aimed at addressing HPV-related carcinoma, Human Papillomavirus Infection, and Head and Neck Neoplasms.